(BTSG) BrightSpring Health - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US10950A1060
Pharmacy, Provider, Infusion, Home-Health, Therapy
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 43.9% |
| Value at Risk 5%th | 66.6% |
| Relative Tail Risk | -7.64% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.88 |
| Alpha | 102.09 |
| CAGR/Max DD | 2.59 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.615 |
| Beta | 1.081 |
| Beta Downside | 1.116 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.56% |
| Mean DD | 8.24% |
| Median DD | 5.12% |
Description: BTSG BrightSpring Health November 09, 2025
BrightSpring Health Services, Inc. (NASDAQ:BTSG) is a U.S.-based home and community-based health-care platform that operates two segments-Pharmacy Solutions and Provider Services-delivering clinical, supportive, and rehabilitative care to Medicare, Medicaid, and commercially insured patients.
Key operational metrics show FY 2023 revenue of approximately $2.2 billion, with an adjusted EBITDA margin hovering around 6%, reflecting modest profitability amid rapid enrollment growth in home-health services.
The company’s growth is propelled by macro trends such as the aging U.S. population, increasing demand for value-based care, and expanding Medicaid enrollment, all of which boost utilization of in-home pharmacy and therapy services.
For a deeper dive into BTSG’s valuation metrics and peer comparisons, the ValueRay platform offers a useful, data-rich view.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (129.6m TTM) > 0 and > 6% of Revenue (6% = 744.8m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA 4.34pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.91% (prev 4.45%; Δ 5.46pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 349.2m > Net Income 129.6m (YES >=105%, WARN >=100%) |
| Net Debt (2.56b) to EBITDA (445.8m) ratio: 5.74 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (218.0m) change vs 12m ago 9.82% (target <= -2.0% for YES) |
| Gross Margin 12.30% (prev 13.81%; Δ -1.50pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 209.8% (prev 172.9%; Δ 36.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.53 (EBITDA TTM 445.8m / Interest Expense TTM 173.6m) >= 6 (WARN >= 3) |
Altman Z'' 1.55
| (A) 0.20 = (Total Current Assets 2.78b - Total Current Liabilities 1.55b) / Total Assets 6.05b |
| (B) -0.02 = Retained Earnings (Balance) -108.6m / Total Assets 6.05b |
| (C) 0.04 = EBIT TTM 266.2m / Avg Total Assets 5.92b |
| (D) -0.03 = Book Value of Equity -113.1m / Total Liabilities 4.23b |
| Total Rating: 1.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 56.98
| 1. Piotroski 4.0pt |
| 2. FCF Yield 3.01% |
| 3. FCF Margin 2.22% |
| 4. Debt/Equity 1.48 |
| 5. Debt/Ebitda 5.74 |
| 6. ROIC - WACC (= -2.70)% |
| 7. RoE 7.52% |
| 8. Rev. Trend 98.23% |
| 9. EPS Trend 46.26% |
What is the price of BTSG shares?
As of December 23, 2025, the stock is trading at USD 38.00 with a total of 1,400,518 shares traded.
Over the past week, the price has changed by +5.67%, over one month by +7.86%, over three months by +37.68% and over the past year by +118.39%.
Over the past week, the price has changed by +5.67%, over one month by +7.86%, over three months by +37.68% and over the past year by +118.39%.
Is BTSG a buy, sell or hold?
BrightSpring Health has received a consensus analysts rating of 4.67.
Therefore, it is recommended to buy BTSG.
- Strong Buy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BTSG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 41.1 | 8.1% |
| Analysts Target Price | 41.1 | 8.1% |
| ValueRay Target Price | 51.2 | 34.8% |
BTSG Fundamental Data Overview December 20, 2025
Market Cap USD = 6.61b (6.61b USD * 1.0 USD.USD)
P/E Trailing = 67.8518
P/E Forward = 35.3357
P/S = 0.4968
P/B = 3.6337
Beta = None
Revenue TTM = 12.41b USD
EBIT TTM = 266.2m USD
EBITDA TTM = 445.8m USD
Long Term Debt = 2.47b USD (from longTermDebt, last quarter)
Short Term Debt = 94.8m USD (from shortTermDebt, last quarter)
Debt = 2.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.56b USD (from netDebt column, last quarter)
Enterprise Value = 9.17b USD (6.61b + Debt 2.70b - CCE 140.3m)
Interest Coverage Ratio = 1.53 (Ebit TTM 266.2m / Interest Expense TTM 173.6m)
FCF Yield = 3.01% (FCF TTM 276.1m / Enterprise Value 9.17b)
FCF Margin = 2.22% (FCF TTM 276.1m / Revenue TTM 12.41b)
Net Margin = 1.04% (Net Income TTM 129.6m / Revenue TTM 12.41b)
Gross Margin = 12.30% ((Revenue TTM 12.41b - Cost of Revenue TTM 10.89b) / Revenue TTM)
Gross Margin QoQ = 11.76% (prev 11.91%)
Tobins Q-Ratio = 1.52 (Enterprise Value 9.17b / Total Assets 6.05b)
Interest Expense / Debt = 1.42% (Interest Expense 38.2m / Debt 2.70b)
Taxrate = 24.43% (12.1m / 49.6m)
NOPAT = 201.2m (EBIT 266.2m * (1 - 24.43%))
Current Ratio = 1.79 (Total Current Assets 2.78b / Total Current Liabilities 1.55b)
Debt / Equity = 1.48 (Debt 2.70b / totalStockholderEquity, last quarter 1.82b)
Debt / EBITDA = 5.74 (Net Debt 2.56b / EBITDA 445.8m)
Debt / FCF = 9.27 (Net Debt 2.56b / FCF TTM 276.1m)
Total Stockholder Equity = 1.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.14% (Net Income 129.6m / Total Assets 6.05b)
RoE = 7.52% (Net Income TTM 129.6m / Total Stockholder Equity 1.72b)
RoCE = 6.35% (EBIT 266.2m / Capital Employed (Equity 1.72b + L.T.Debt 2.47b))
RoIC = 4.71% (NOPAT 201.2m / Invested Capital 4.27b)
WACC = 7.41% (E(6.61b)/V(9.31b) * Re(10.0%) + D(2.70b)/V(9.31b) * Rd(1.42%) * (1-Tc(0.24)))
Discount Rate = 10.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.84%
[DCF Debug] Terminal Value 62.16% ; FCFE base≈170.9m ; Y1≈112.2m ; Y5≈51.3m
Fair Price DCF = 4.18 (DCF Value 754.2m / Shares Outstanding 180.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 46.26 | EPS CAGR: 11.73% | SUE: -0.69 | # QB: 0
Revenue Correlation: 98.23 | Revenue CAGR: 22.35% | SUE: 1.21 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.25 | Chg30d=-0.002 | Revisions Net=+3 | Analysts=9
EPS next Year (2026-12-31): EPS=1.33 | Chg30d=+0.006 | Revisions Net=+3 | Growth EPS=+29.0% | Growth Revenue=+14.7%
P/E Trailing = 67.8518
P/E Forward = 35.3357
P/S = 0.4968
P/B = 3.6337
Beta = None
Revenue TTM = 12.41b USD
EBIT TTM = 266.2m USD
EBITDA TTM = 445.8m USD
Long Term Debt = 2.47b USD (from longTermDebt, last quarter)
Short Term Debt = 94.8m USD (from shortTermDebt, last quarter)
Debt = 2.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.56b USD (from netDebt column, last quarter)
Enterprise Value = 9.17b USD (6.61b + Debt 2.70b - CCE 140.3m)
Interest Coverage Ratio = 1.53 (Ebit TTM 266.2m / Interest Expense TTM 173.6m)
FCF Yield = 3.01% (FCF TTM 276.1m / Enterprise Value 9.17b)
FCF Margin = 2.22% (FCF TTM 276.1m / Revenue TTM 12.41b)
Net Margin = 1.04% (Net Income TTM 129.6m / Revenue TTM 12.41b)
Gross Margin = 12.30% ((Revenue TTM 12.41b - Cost of Revenue TTM 10.89b) / Revenue TTM)
Gross Margin QoQ = 11.76% (prev 11.91%)
Tobins Q-Ratio = 1.52 (Enterprise Value 9.17b / Total Assets 6.05b)
Interest Expense / Debt = 1.42% (Interest Expense 38.2m / Debt 2.70b)
Taxrate = 24.43% (12.1m / 49.6m)
NOPAT = 201.2m (EBIT 266.2m * (1 - 24.43%))
Current Ratio = 1.79 (Total Current Assets 2.78b / Total Current Liabilities 1.55b)
Debt / Equity = 1.48 (Debt 2.70b / totalStockholderEquity, last quarter 1.82b)
Debt / EBITDA = 5.74 (Net Debt 2.56b / EBITDA 445.8m)
Debt / FCF = 9.27 (Net Debt 2.56b / FCF TTM 276.1m)
Total Stockholder Equity = 1.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.14% (Net Income 129.6m / Total Assets 6.05b)
RoE = 7.52% (Net Income TTM 129.6m / Total Stockholder Equity 1.72b)
RoCE = 6.35% (EBIT 266.2m / Capital Employed (Equity 1.72b + L.T.Debt 2.47b))
RoIC = 4.71% (NOPAT 201.2m / Invested Capital 4.27b)
WACC = 7.41% (E(6.61b)/V(9.31b) * Re(10.0%) + D(2.70b)/V(9.31b) * Rd(1.42%) * (1-Tc(0.24)))
Discount Rate = 10.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.84%
[DCF Debug] Terminal Value 62.16% ; FCFE base≈170.9m ; Y1≈112.2m ; Y5≈51.3m
Fair Price DCF = 4.18 (DCF Value 754.2m / Shares Outstanding 180.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 46.26 | EPS CAGR: 11.73% | SUE: -0.69 | # QB: 0
Revenue Correlation: 98.23 | Revenue CAGR: 22.35% | SUE: 1.21 | # QB: 3
EPS next Quarter (2026-03-31): EPS=0.25 | Chg30d=-0.002 | Revisions Net=+3 | Analysts=9
EPS next Year (2026-12-31): EPS=1.33 | Chg30d=+0.006 | Revisions Net=+3 | Growth EPS=+29.0% | Growth Revenue=+14.7%
Additional Sources for BTSG Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle